Skip to main content

Table 1 Baseline characteristics of the study population

From: PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma

Variables All patients Analysis group Validation group P value
Sex F/M 14/109 9/64 5/45 0.69
Age (years) 57.94 ± 10.96 57.88 ± 10.03 58.02 ± 12.29 0.94
ALT (U/L) 30 (8–471.1) 27 (10–261) 35.5 (8–471.1) 0.30
AST (U/L) 47 (13–544) 38 (13–291) 52.5 (16–544) 0.06
TBiL (μmol/L) 18.3 (8.5–457) 17.8 (8.5–457.0) 20.0 (8.9–113.2) 0.41
ALB (g/L) 36.53 ± 4.91 36.98 ± 4.78 35.87 ± 5.06 0.22
D-Dimer (mg/L) 0.80 (0.10–15.61) 1.1 (0.27–15.61) 0.72 (0.10–13.95) 0.23
PTA (%) 80.62 ± 14.57 82.31 ± 12.92 78.14 ± 16.51 0.12
PLT (× 109/L) 162.09 ± 99.10 161.96 ± 102.87 162.28 ± 94.37 0.97
AFP 441.06 (1.33–1210.0) 393.09 (1.33–1210.0) 511.09 (1.5–1210) 0.38
PIVKA-II (mAU/ml) 278.13 (1.6–75,000.00) 196.12 (12–75,000.00) 514.86 (1.6–75,000) 0.45
Liver cirrhosis
 YES/NO 105/18 30/5 75/13 0.95
Child-Pugh grade
 A 68 37 31 0.27
 B 55 36 19  
PVTT, type
 I 34 21 13 0.91
 II 51 30 21  
 III 19 12 7  
 IV 19 10 9  
BCLC stage
 A 12 9 3 0.48
 B 76 43 33  
 C 35 21 14  
 HBsAg (COI) 4578 (12.2–8657.0) 4512 (12.2–7542.0) 5221.5 (35–8657.0) 0.38
HBeAg
 Positive 55 32 23 0.81
 Negative 68 41 27  
 HBV-DNA (IU/L) 7500.0 (0.0–4.16 × 107) 5800.0 (0.0–4.16 × 107) 21,750.0 (0.0–3.26 × 107) 0.46